CN101563457A - 利用hplc在制备级上纯化rna的方法 - Google Patents
利用hplc在制备级上纯化rna的方法 Download PDFInfo
- Publication number
- CN101563457A CN101563457A CNA2007800471332A CN200780047133A CN101563457A CN 101563457 A CN101563457 A CN 101563457A CN A2007800471332 A CNA2007800471332 A CN A2007800471332A CN 200780047133 A CN200780047133 A CN 200780047133A CN 101563457 A CN101563457 A CN 101563457A
- Authority
- CN
- China
- Prior art keywords
- rna
- phase
- hplc
- porous
- moving phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Abstract
Description
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006061015A DE102006061015A1 (de) | 2006-12-22 | 2006-12-22 | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102006061015.6 | 2006-12-22 | ||
PCT/EP2007/011294 WO2008077592A1 (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101563457A true CN101563457A (zh) | 2009-10-21 |
CN101563457B CN101563457B (zh) | 2014-03-12 |
Family
ID=39186980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780047133.2A Active CN101563457B (zh) | 2006-12-22 | 2007-12-20 | 利用hplc在制备级上纯化rna的方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8383340B2 (zh) |
EP (1) | EP2092064B1 (zh) |
JP (1) | JP5307724B2 (zh) |
KR (1) | KR101183173B1 (zh) |
CN (1) | CN101563457B (zh) |
AT (1) | ATE481482T1 (zh) |
AU (1) | AU2007338360B2 (zh) |
CA (1) | CA2670727C (zh) |
DE (2) | DE102006061015A1 (zh) |
DK (1) | DK2092064T3 (zh) |
ES (1) | ES2352306T3 (zh) |
PL (1) | PL2092064T3 (zh) |
WO (1) | WO2008077592A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115774075A (zh) * | 2023-02-15 | 2023-03-10 | 江苏耀海生物制药有限公司 | 一种基于RP-HPLC分析体外转录产物成分circRNA的方法 |
Families Citing this family (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
EP2324131A4 (en) * | 2008-09-17 | 2013-02-27 | Ge Healthcare Bio Sciences | PROCESS FOR ISOLATING SMALL RNA |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2955230A1 (en) | 2010-07-30 | 2015-12-16 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
KR20140139101A (ko) | 2012-03-27 | 2014-12-04 | 큐어백 게엠바하 | 5''top utr을 포함하는 인공 핵산 분자 |
DK2831241T3 (da) | 2012-03-27 | 2017-11-06 | Curevac Ag | Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression. |
CA2866955A1 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
CA2903487A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger rna |
PL2970948T3 (pl) | 2013-03-15 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Sposoby oczyszczania rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2014144711A1 (en) * | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
EP2996697B1 (en) | 2013-05-15 | 2019-06-26 | Robert Kruse | Intracellular translation of circular rna |
JP7019233B2 (ja) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法 |
KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
EP3450561A1 (en) | 2013-08-21 | 2019-03-06 | CureVac AG | Method for increasing expression of rna-encoded proteins |
EP3035960B1 (en) | 2013-08-21 | 2019-07-03 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
EP4043032A1 (en) | 2013-08-21 | 2022-08-17 | CureVac AG | Rabies vaccine |
ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
EP3542802A1 (en) | 2013-11-01 | 2019-09-25 | CureVac AG | Modified rna with decreased immunostimulatory properties |
SG10201903381TA (en) | 2013-12-30 | 2019-05-30 | Curevac Ag | Artificial nucleic acid molecules |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
US10307472B2 (en) | 2014-03-12 | 2019-06-04 | Curevac Ag | Combination of vaccination and OX40 agonists |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
CN106659803A (zh) | 2014-04-23 | 2017-05-10 | 摩登纳特斯有限公司 | 核酸疫苗 |
BR112016026980B1 (pt) | 2014-06-10 | 2022-05-03 | Curevac Real Estate Gmbh | Método para sintetizar uma molécula de rna de uma dada sequência |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
JP2017522028A (ja) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 環状ポリヌクレオチド |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
US10780054B2 (en) | 2015-04-17 | 2020-09-22 | Curevac Real Estate Gmbh | Lyophilization of RNA |
AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
CA2975816A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
SG11201708540VA (en) | 2015-05-20 | 2017-12-28 | Curevac Ag | Dry powder composition comprising long-chain rna |
PT4108769T (pt) | 2015-05-29 | 2023-10-10 | Curevac Mfg Gmbh | Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
EP3317424B1 (en) * | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
WO2017064146A1 (en) | 2015-10-12 | 2017-04-20 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
ES2914225T3 (es) | 2015-10-16 | 2022-06-08 | Modernatx Inc | Análogos de cap de ARNm con enlace de fosfato modificado |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
JP2018530587A (ja) | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | mRNAキャップ類似体およびmRNAキャッピングの方法 |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
SI3394030T1 (sl) | 2015-12-22 | 2022-04-29 | Modernatx, Inc. | Sestave za doziranje sredstev v celice |
CN108778308A (zh) | 2015-12-22 | 2018-11-09 | 库瑞瓦格股份公司 | 生产rna分子组合物的方法 |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017137095A1 (en) | 2016-02-12 | 2017-08-17 | Curevac Ag | Method for analyzing rna |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
SG10201913630YA (en) | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
LT3445850T (lt) | 2016-04-22 | 2021-11-25 | BioNTech SE | Viengrandės rnr gavimo būdas |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
US11141474B2 (en) | 2016-05-04 | 2021-10-12 | Curevac Ag | Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
EP3468609A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Cationic carriers for nucleic acid delivery |
MX2018013919A (es) | 2016-06-09 | 2019-04-15 | Curevac Ag | Portadores hibridos para cargas de acido nucleico. |
CA3027201A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CA3025812A1 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
WO2018053209A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
KR20190093816A (ko) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018096179A1 (en) * | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
EP3551230A1 (en) | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
WO2018141371A1 (en) | 2017-01-31 | 2018-08-09 | Curevac Ag | Purification and/or formulation of rna |
HUE060693T2 (hu) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Vegyület és készítmények terápiás szerek intracelluláris bejuttatására |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
JP2020514370A (ja) | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤 |
AU2018240515A1 (en) | 2017-03-24 | 2019-08-01 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
MA49922A (fr) * | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
US20200362382A1 (en) | 2017-08-18 | 2020-11-19 | Modernatx, Inc. | Methods of preparing modified rna |
US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
US11525158B2 (en) | 2017-12-21 | 2022-12-13 | CureVac SE | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA |
EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
EP3781591A1 (en) | 2018-04-17 | 2021-02-24 | CureVac AG | Novel rsv rna molecules and compositions for vaccination |
US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
BR112020025601A8 (pt) | 2018-06-28 | 2022-07-05 | Tesla Automation GmbH | Biorreator para a transcrição in vitro de rna |
WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
CA3114892A1 (en) | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
EP3897702A2 (en) | 2018-12-21 | 2021-10-27 | CureVac AG | Rna for malaria vaccines |
MX2021009245A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Metodos de preparacion de nanoparticulas lipidicas. |
MX2021009236A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Agitadores vorticiales y metodos, sistemas y aparatos asociados de estos. |
EP3920950A1 (en) | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
BR112022001947A2 (pt) | 2019-08-14 | 2022-09-20 | Curevac Ag | Combinações e composições de rna com propriedades imunoestimuladoras reduzidas |
EP4076647A1 (en) | 2019-12-20 | 2022-10-26 | CureVac AG | Lipid nanoparticles for delivery of nucleic acids |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
DE112021000012B4 (de) | 2020-02-04 | 2023-08-31 | CureVac SE | Coronavirus-Vakzine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
EP4127704A1 (en) * | 2020-03-25 | 2023-02-08 | Waters Technologies Corporation | Devices and methods for the sensitive detection and quantitation of biomolecules |
AU2021254312B2 (en) | 2020-04-09 | 2024-01-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
TW202204622A (zh) | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | 針對冠狀病毒之核酸疫苗 |
EP3993828A1 (en) | 2020-05-29 | 2022-05-11 | CureVac AG | Nucleic acid based combination vaccines |
WO2021254593A1 (en) | 2020-06-15 | 2021-12-23 | Curevac Ag | Analysis of nucleic acid mixtures |
JP2023532707A (ja) | 2020-06-30 | 2023-07-31 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
US20230272052A1 (en) | 2020-07-31 | 2023-08-31 | CureVac SE | Nucleic acid encoded antibody mixtures |
AU2021328980A1 (en) | 2020-08-20 | 2023-03-09 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
EP4208286A1 (en) | 2020-09-01 | 2023-07-12 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
WO2022112498A1 (en) | 2020-11-27 | 2022-06-02 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
CN116615472A (zh) | 2021-01-14 | 2023-08-18 | 苏州艾博生物科技有限公司 | 聚合物缀合的脂质化合物和脂质纳米颗粒组合物 |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022164428A1 (en) | 2021-01-27 | 2022-08-04 | New England Biolabs, Inc. | Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits |
CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
US11028379B1 (en) | 2021-01-27 | 2021-06-08 | New England Biolabs, Inc. | FCE mRNA capping enzyme compositions, methods and kits |
CN117377491A (zh) | 2021-03-26 | 2024-01-09 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
WO2022240960A1 (en) * | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
WO2022247755A1 (en) | 2021-05-24 | 2022-12-01 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022256597A1 (en) | 2021-06-04 | 2022-12-08 | Translate Bio, Inc. | Assay for quantitative assessment of mrna capping efficiency |
CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
WO2023014649A1 (en) | 2021-08-02 | 2023-02-09 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
KR102646914B1 (ko) * | 2021-10-01 | 2024-03-12 | 서울대학교산학협력단 | 아실글리세롤 이성질체 및 자유지방산 직접 동시분석법 및 이를 통한 라이페이스 입체선택성 분석법 |
CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
WO2023056917A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023196950A1 (en) | 2022-04-07 | 2023-10-12 | New England Biolabs, Inc. | Methods of higher fidelity rna synthesis |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024030369A1 (en) | 2022-08-01 | 2024-02-08 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography for mrna purity assessment |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2468048A1 (en) | 1994-02-23 | 1995-08-31 | Pamela Pavco | Process for purifying chemically synthesized rna |
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
US20020102563A1 (en) | 1998-04-24 | 2002-08-01 | Gjerde Douglas T. | Apparatus and method for separating and purifying polynucleotides |
WO2001046687A2 (en) | 1999-12-22 | 2001-06-28 | Transgenomic, Inc. | System and method for automated matched ion polynucleotide chromatography |
US7655790B2 (en) * | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
US7125492B2 (en) * | 2003-07-17 | 2006-10-24 | Agilent Technologies, Inc. | Additives for reversed-phase HPLC mobile phases |
US7781573B2 (en) * | 2006-08-03 | 2010-08-24 | Nam Q Ngo | Multi layer chromatography of nucleic acids |
DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
-
2006
- 2006-12-22 DE DE102006061015A patent/DE102006061015A1/de not_active Ceased
-
2007
- 2007-12-20 PL PL07857017T patent/PL2092064T3/pl unknown
- 2007-12-20 CA CA2670727A patent/CA2670727C/en active Active
- 2007-12-20 WO PCT/EP2007/011294 patent/WO2008077592A1/en active Application Filing
- 2007-12-20 DE DE602007009295T patent/DE602007009295D1/de active Active
- 2007-12-20 ES ES07857017T patent/ES2352306T3/es active Active
- 2007-12-20 AU AU2007338360A patent/AU2007338360B2/en active Active
- 2007-12-20 AT AT07857017T patent/ATE481482T1/de active
- 2007-12-20 DK DK07857017.3T patent/DK2092064T3/da active
- 2007-12-20 EP EP07857017A patent/EP2092064B1/en active Active
- 2007-12-20 JP JP2009541898A patent/JP5307724B2/ja active Active
- 2007-12-20 US US12/520,172 patent/US8383340B2/en active Active
- 2007-12-20 CN CN200780047133.2A patent/CN101563457B/zh active Active
- 2007-12-20 KR KR1020097012957A patent/KR101183173B1/ko active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115774075A (zh) * | 2023-02-15 | 2023-03-10 | 江苏耀海生物制药有限公司 | 一种基于RP-HPLC分析体外转录产物成分circRNA的方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE481482T1 (de) | 2010-10-15 |
KR20090098968A (ko) | 2009-09-18 |
WO2008077592A1 (en) | 2008-07-03 |
CN101563457B (zh) | 2014-03-12 |
DE102006061015A1 (de) | 2008-06-26 |
EP2092064B1 (en) | 2010-09-15 |
JP5307724B2 (ja) | 2013-10-02 |
KR101183173B1 (ko) | 2012-09-14 |
AU2007338360B2 (en) | 2011-06-02 |
CA2670727A1 (en) | 2008-07-03 |
DE602007009295D1 (de) | 2010-10-28 |
JP2010512767A (ja) | 2010-04-30 |
EP2092064A1 (en) | 2009-08-26 |
CA2670727C (en) | 2012-10-09 |
ES2352306T3 (es) | 2011-02-17 |
US8383340B2 (en) | 2013-02-26 |
AU2007338360A1 (en) | 2008-07-03 |
DK2092064T3 (da) | 2010-12-13 |
PL2092064T3 (pl) | 2011-03-31 |
US20100048883A1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101563457B (zh) | 利用hplc在制备级上纯化rna的方法 | |
Eon-Duval et al. | Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process | |
Swanson et al. | The mitochondrial ribosome of Xenopus laevis | |
US20060105456A1 (en) | Method for purifying adenoviruses | |
WO2008063717A2 (en) | Pharmaceutical manufacturing methods | |
JPH09508283A (ja) | イソプロパノール含有水溶液を用いる核酸のトランスフェクション効率の増強 | |
Andrus et al. | Analysis and purification of synthetic nucleic acids using HPLC | |
EP1444249A1 (en) | Method of protein purification | |
Kibwage et al. | Separation of erythromycin and related substances by high-performance liquid chromatography on poly (styrene-divinylbenzene) packing materials | |
Glitz et al. | Nucleotide sequences at the 5′-linked ends of viral ribonucleic acids | |
Valenzuela et al. | Isolation and assay of eukaryotic DNA-dependent RNA polymerases | |
Burness et al. | Overestimates of the size of poly (A) segments | |
Spencer et al. | A single-step purification of bothropstoxin-1 | |
Weatherford et al. | Separation of Escherichia, coli ribonucleases on a DNA agarose column and the identification of an RNase H activity | |
Graeve et al. | Fractionation of biologically active messenger RNAs by HPLC gel filtration | |
WO2000059927A1 (en) | Purification of biological preparations | |
JP4125605B2 (ja) | 酢酸を含まない、ハイドロキシアパタイトによるプラスミドdnaの精製 | |
Gomes et al. | Applications of gellan natural polymer microspheres in recombinant catechol-O-methyltransferase direct capture from a Komagataella pastoris lysate | |
Foriers et al. | Use of high-performance size-exclusion chromatography for the separation of poliovirus and subviral particles | |
Samaraweera et al. | Separation of insect hemolymph proteins by cascade‐mode multiaffinity chromatography | |
Sawata et al. | Development of an advanced polysome display system dependant on a specific protein-RNA motif interaction | |
Hurst et al. | The TNT® T7 Quick Coupled Transcription/Translation System | |
Malburet et al. | mRNA extraction from lipid nanoparticles | |
Hayashi et al. | Purification and properties of the major phenylalanyl transfer RNA species in drug-resistant Ehrlich tumor cells | |
Hancock et al. | Biochemical applications of preparative liquid chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Tubingen Patentee after: CUREVAC AG Address before: Germany Tubingen Patentee before: Curevac GmbH |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200203 Address after: Tubingen, Germany Patentee after: Kuriwag Real Estate Co.,Ltd. Address before: Tubingen, Germany Patentee before: CureVac AG |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Tubingen Patentee after: kuriwag manufacturing Co.,Ltd. Address before: Tubingen Patentee before: Kuriwag Real Estate Co.,Ltd. |